Ernexa Therapeutics (ERNAW) Depreciation & Amortization (CF) (2010 - 2026)

Ernexa Therapeutics has reported Depreciation & Amortization (CF) for 17 years, with the latest figure at $8000.0 in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 55.56% year-over-year to $8000.0; the trailing twelve-month figure through Mar 2026 stood at $55000.0 (down 53.39% YoY), and the FY2025 full-year result was $65000.0, down 53.24% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $8000.0, down from $13000.0 in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $68000.0 in Q2 2022, with the low at $8000.0 in Q1 2026.
• Historically, Depreciation & Amortization (CF) has averaged $26882.4 across 5 years, with a median of $21000.0 in 2023.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) slumped 69.12% — and 2024, when it surged 109.52%.
• Ernexa Therapeutics' Depreciation & Amortization (CF) stood at $17000.0 in 2022, then grew by 29.41% to $22000.0 in 2023, then decreased by 13.64% to $19000.0 in 2024, then slumped by 31.58% to $13000.0 in 2025, then slumped by 38.46% to $8000.0 in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $8000.0 (Q1 2026), $13000.0 (Q4 2025), and $17000.0 (Q3 2025), per Business Quant data.